linjc16/ctgov huggingface dataset:
Nutrition Effects on Fatigue During Tennis Playing

Study Overview
=================
Brief Summary
-----------------
The main objective of this study is to investigate the effects of ingestion of different sports drinks (Nutrattente / Nutraperf / Nutrarecup) on fatigue induced by a tennis tournament simulation.

Official Title
-----------------
Effects of Ingestion of Different Sports Drinks on Fatigue During Playing Tennis

Conditions
-----------------
Fatigue

Intervention / Treatment
-----------------
* Dietary Supplement: Nutrattente / Nutraperf / Nutrarecup
* Dietary Supplement: Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: About 18 to 35 years (inclusive) Subject has a stable weight for at least three months before the start of the study Subject able and willing to comply with the protocol and agreeing to give their consent in writing Subject affiliated with a social security scheme Subject willing to be included in the national register of volunteers who lend themselves to biomedical research

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sports Drinks<br>3 drinks : Nutrattente (before each match) / Nutraperf (during each match) / Nutrarecup (after each match) | Dietary Supplement: Nutrattente / Nutraperf / Nutrarecup<br>* 500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match<br>|
| Placebo Comparator: Placebo<br>3 drinks : Nutrattente placebo (before each match) / Nutraperf placebo(during each match) / Nutrarecup placebo (after each match) | Dietary Supplement: Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo<br>* 500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peripheral fatigue measured by surface electromyographic (EMG) signal from the right triceps muscle |  | 3 matches (1.5 days) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fatigue, Tennis, Nutrition, Tournament simulation, Delivery of Health Care
Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
This study is to examine the change of fasting insulin, glucose, insulin sensitivity and related traits in response to the six month treatment of omega-3 fatty acids, including fish oil and flaxseed oil, in Chinese type 2 diabetic patients. Corn oil, rich in omega-6 fatty acids, will be selected as a controlled oil. The investigators hypothesize that omega-3 fatty acids could improve insulin sensitivity and glucose metabolism in Chinese type 2 diabetic patients.

Detailed Description
-----------------
The insulin resistance will be estimated by a homeostatic model assessment model of insulin resistance (HOMA-IR)

Conditions
-----------------
Type 2 Diabetes, Insulin Resistance

Intervention / Treatment
-----------------
* Dietary Supplement: Fish Oil Supplementation
* Dietary Supplement: Flaxseed Oil Supplementation
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Fasting glucose > 7.0 or have diabetes medication; Male, 35-80 years; female, postmenopausal to 80 years; Agree to participant in the trial. Exclusion Criteria: Deny to sign the informed consent; type 1 diabetes; Family history of hypertriglyceridemia or fasting triglyceride>4.56 mmol/L; Have severe liver disease, kidney disease or cancer; Participating in the other clinical trial within 30 days; Other diseases or conditions, for which the doctor of the patients do not agree his or her participating.

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fish Oil Supplementation<br>Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA. | Dietary Supplement: Fish Oil Supplementation<br> <br> |
| Experimental: Flaxseed Oil Supplementation<br>Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA | Dietary Supplement: Flaxseed Oil Supplementation<br> <br> |
| Placebo Comparator: Placebo Supplementation<br>Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil. | Dietary Supplement: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insulin resistance |  | 180 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
omega-3 fatty acids, randomized controlled trial
Medical Data Collection for the Evaluation of Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine

Study Overview
=================
Brief Summary
-----------------
This study collects data on the use of radiofrequency ablation and cement augmentation for the treatment of cancer that has spread to the spine (metastases to the spine). Radiofrequency ablation with cement augmentation is a useful approach for the treatment of secondary metastasis to the spine. Information collected in this study may help doctors to learn the effectiveness of this therapy, and may help to evaluate optimal technique, appropriate patient selection, and management of complications.

Detailed Description
-----------------
PRIMARY OBJECTIVE: I. To evaluate the use of radiofrequency ablation and cement augmentation for the treatment of secondary metastases to the spine. OUTLINE: Patients' medical data is collected retrospectively.

Official Title
-----------------
A Single-Center Retrospective Study Evaluating Radiofrequency Ablation and Cement Augmentation for the Treatment of Secondary Metastases to the Spine

Conditions
-----------------
Metastatic Malignant Neoplasm in the Spine

Intervention / Treatment
-----------------
* Other: Electronic Health Record Review


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent radiofrequency ablation with cement augmentation at the Department of Interventional Radiology at MD Anderson Cancer Center (MDACC) between 1/1/2017 and 9/26/2020 Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observational (data collection)<br>Patients' medical data is collected retrospectively. | Other: Electronic Health Record Review<br>* Medical data is collected<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Technical success | Results will be compared with data available from other published literature. | Up to 3 years | 
| Clinical success | Results will be compared with data available from other published literature. | Up to 3 years | 
| Complication rates | Results will be compared with data available from other published literature. | Up to 3 years |
Post-operative Cognitive Function Following Pelvic Floor Surgery

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess cognitive function before and after surgery for pelvic organ prolapse using sensitive tests of various neurocognitive domains.

Detailed Description
-----------------
Post operative cognitive dysfunction has been well described as a relatively common phenomenon with potentially long-lasting detrimental effects. However, there are currently limited data exploring the effects of gynecologic surgery on cognitive function. The population of patients treated surgically for pelvic floor disorders is typically older, and therefore at higher baseline risk for cognitive dysfunction. Therefore, it is of interest to determine the effects of pelvic floor surgery and anesthesia on this patient population. The investigators plan to conduct a prospective cohort study to assess cognitive function before and after pelvic organ prolapse surgery using sensitive tests of memory and other neurocognitive domains. Participants will be women undergoing surgery for pelvic organ prolapse. All participants will undergo cognitive tests at three time points: at their pre-operative clinic appointment, in the hospital the morning after surgery, and at their post-operative clinic appointment. In addition to the neurocognitive tests, patients will undergo a series of questionnaires regarding physical function, frailty, sleep quality, and incontinence symptoms.

Official Title
-----------------
Post-operative Cognitive Function Following Pelvic Floor Surgery

Conditions
-----------------
Pelvic Organ Prolapse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women 60 years of age or older who are scheduled to undergo surgery for pelvic organ prolapse. Exclusion Criteria: Women who have a known baseline diagnosis of cognitive dysfunction or central nervous disorder A Mini-Mental State Exam (MMSE) score of greater than 24 Non-english speaking Any severe visual or auditory disorder Alcoholism or drug dependence

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in episodic memory neurocognitive test scores | Episodic memory will be assessed using the Scene Encoding/Recognition Test | 8 weeks |
Dual Task Performance in Community Dwelling Older Adults

Study Overview
=================
Brief Summary
-----------------
Dual task performances may be impaired with the impairment in motor performance and cognitive functions due to aging. The aim of the present study is to investigate the gender differences in dual task performance. A total of 82 community dwelling older adults (41 males and 41 females) aged between 65 and 75 years were included in the study. Motor performance was evaluated with sit-to-stand test, the timed up and go test, 10 m walking test and cognitive functions were evaluated with Montreal Cognitive Assessment Test. Dual task performances were evaluated as motor-motor and cognitive-motor performance.

Official Title
-----------------
The Relationship Between Cognitive and Motor Functions, and Dual Task Performance in Community Dwelling Older Adults: Gender Differences

Conditions
-----------------
Dual Task, Community Dwelling Older Adult

Intervention / Treatment
-----------------
* Other: dual task performance


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The individuals aged between 65 and 75 years, who agreed for participation, who received 8 or higher points from Hodkinson Mental test, who had no neurologic/orthopedic problems that could affect balance and walking, or communication problem were included in the study. Exclusion Criteria: The individuals who were using 3 or more medications that could affect motor and cognitive functions, and the ones who could not complete the tests were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gender difference<br>dual task performance | Other: dual task performance<br>* dual task performance measurement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dual Task Performance | Assessment of Dual Task Performance | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montreal Cognitive Assessment Scale | Assessment of Cognitive Functions | 5 minutes | 
| Timed Up and Go | Assessment of Physical Performance | 5 minutes | 
| 30 Seconds Sit-to-Stand Test | Assessment of Physical Performance | 5 minutes | 
| 10 Meter Walking Test | Assessment of Physical Performance | 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dual task, community dwelling older adult, cognitive status, motor performance
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety of Velcade when used with chemoradiation in cancer patients.

Detailed Description
-----------------
To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of Velcade® when administered as a twice weekly 3-5 second IV bolus every 3 weeks to patients with malignancies of the brain, head and neck and cervix who receive 2-8 weeks of chemoradiation. To evaluate the safety and toxicity profile of Velcade® when administered on a twice weekly (days 1, 4, 8 and 11) every 3 weeks (maximum 8 weeks) concurrent with chemoradiation. To evaluate tumor response

Official Title
-----------------
A Phase I Open-labeled, Dose-escalation, Safety Study of the Combination of Velcade and Chemoradiation for the Treatment of Cancer Patients

Conditions
-----------------
Cervix Cancer, Brain Cancer, Head and Neck Cancer, Central Nervous System Neoplasms

Intervention / Treatment
-----------------
* Drug: Velcade (bortezomib)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed malignancy Requiring at least grade 2 weeks of radiation therapy Solid tumors of the central nervous system, head and neck area, and cervix World Health Organization (WHO) performance status equal to or less than 2 Exclusion Criteria: Equal to or greater than grade 2 peripheral neuropathy Myocardial infarction within 6 months Hypersensitivity to bortezomib, boron, or mannitol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CNS<br>Velcade (bortezomib) | Drug: Velcade (bortezomib)<br> <br> |
| Experimental: Head and Neck<br>Velcade (bortezomib) | Drug: Velcade (bortezomib)<br> <br> |
| Experimental: Cervix<br>Velcade (bortezomib) | Drug: Velcade (bortezomib)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the safe and maximum tolerated dose of Velcade® when administered as a twice weekly 3-5 second intravenous (IV) bolus every 3 weeks to patients with malignancies of the brain, head and neck, and cervix who receive 2-8 weeks of radiotherapy |  | 2-8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malignancies of the central nervous system, head and neck area, and cervix
Histopathology of the Aspirated Thrombus During Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
This study was initiated on the preliminary premise that a thrombus whose formation was triggered by a thrombogenic substrate, such as within an atherosclerotic plaque (Tissue factor initiated thrombus), may evolve differently than the one evolving at the site of a recently implanted stent (foreign body triggered). Consequently, the thrombus composition of a de novo clot could differ from the other one, extracted during the occurrence of a subacute thrombosis, regarding the number of various cells, the amount of fibrin and platelet aggregates and the relationship among these components. In addition, it seems relevant to evaluate the numbers and the distribution of the local monocytes, once these cells may interact with platelets (via cell -adhesion mechanisms e.g., by CD31 [PECAM-1]) and by the extrinsic coagulation pathway (via TF/FVII elaborated by plaque-resident macrophages). Such a distinction, if eventually found, may reveal the mechanisms of thrombosis within coronary arteries, and may have clinical implications.

Conditions
-----------------
Thrombosis, Acute Coronary Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with acute coronary syndrome who undergo angiography Evidence of coronary thrombus Undergo aspiration procedure yielding thrombus fragments Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Aspirated Coronary Thrombi During AMI<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of Possible Difference in Composition of Thrombi Aspirated during Acute Myocardial Infarction Precipitated by de novo vs Subacute Thrombosis | Analysis of thrombotic specimen contents aspirated during Acute Myocardial Infarction by searching for possible differences in the components of the thrombotic debris, whether cellular, or fibrin and platelets, in accordance with clinical parameters. | two years |
Effects of Combinations of Performance-enhancing Supplements on Exercise Performance

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate the effect of combinations of creatine monohydrate, sodium bicarbonate and caffeine on exercise performance and fatigability.

Official Title
-----------------
Effects of Different Combinations of Performance-enhancing Supplements on High Intensity Exercise Performance

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Dietary Supplement: Sodium bicarbonate and caffeine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy VO2max of >50 ml/min/kg for men and >45 ml/min/kg for women Performs endurance training >3 times per week Exclusion Criteria: Chronic disease deemed by the study responsible medical doctor to interfere with any part of the study Smoking Chronic use of prescription medicine deemed by the study responsible medical doctor to interfere with any part of the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Creatine<br>Subjects ingest creatine monohydrate daily. | Dietary Supplement: Sodium bicarbonate and caffeine<br>* On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.<br>|
| Placebo Comparator: Placebo<br>Subjects ingest placebo daily. | Dietary Supplement: Sodium bicarbonate and caffeine<br>* On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Work performed (kJ/Watt) | Work performed during a 6 minute time trial | Measured at each trial throughout the study, on average 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Work performed (kJ/Watt) | Work performed during a 15 second sprint test | Measured at each trial throughout the study, on average 4 weeks | 
| Muscle strength (Nm) | Maximal voluntary isometric contraction of m. quadriceps femoris | Measured at each trial throughout the study, on average 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise, Performance, Supplementation